Somatostatin Receptor Imaging and Small Cell Lung Ca

Tc99m Depreotide Scan (NeoTect): Small cell lung cancer in the left lower lobe with possible metastatic left axillary lymph node. There is some more subtle mediastinal activity as well.

Somatostatin is a 14-amino-acid peptide hormone found on many cells of neuroendocrine origin. It acts as a neurotransmitter in the central nervous system. When it binds to cells, it inhibits the release of growth hormone, insulin, glucagon, and gastrin. Somatostatin receptors have been found on the surface of many human tumor cells including APUD cells (amine precursor uptake and decarboxylation) such as pituitary tumors, pancreatic endocrine tumors, carcinoids, paragangliomas, small cell lung cancers, medullary thyroid carcinomas and pheochromocytomas. Small cell lung cancer (SCLC) tumors have neuroendocrine features. In vitro and in vivo studies have demonstrated that 50%-75% of SCLC tumors express receptors for somatostatin. Non-APUD tumor cells have somatostatin receptors, including activated lymphocytes, astrocytomas, and some breast carcinoma. Studies have shown that somatostatin analogs may inhibit growth of many of these tumors in vivo in animal studies. Tumors such as non small cell lung cancer that do not express somatostatin receptors are nonetheless imaged. One possible explanation of this finding is that the uptake of tracer is not by the receptor-negative tumor but by the surrounding tissues such as somatostatin receptor-positive white blood cells or neuroendocrine cells nearby the primary tumors. In-111-DTPA-D-Phe1]-octreotide was found to have a high affinity for somatostatin receptors . The compound, also called OctreoScan, is easily labeled with In-111. Since this radiotracer is mainly eliminated via the kidneys, intra-abdominal evaluation of somatostatin-receptor positive tumors could be performed. Tc99m Depreotide (NeoTect) is a somatostatin peptide analog labled with Technetium. FDG PET has decreased the use of somatostatin receptor scintigraphy for lung cancer.

Neurofibrosarcoma in NF1 Patient. PET / MR Fusion

Click on Image for Larger View

Young adult female with known NF1 and multiple peripheral neuromas. The patient had a prior neurofibrosarcoma in the left sacral plexus resected 4 years ago. She presented to another hospital for pain and on a routine MRI of the lumbar spine a suspicicious area was noted. PET / CT was done at our facility and I fused it to the T2 axial Lsp MRI above. The patient has a recurrent neurofibrosarcoma in the left sacral plexus.

Type A Aortic Disection with Pericardial Hematoma

CT chest: Type A Aortic disection with rupture into pericardial space. Note the intimal flap in the ascending aorta and the intermediate density blood in the pericardial space.
Click image for full size

Pathophysiology
tear in intimal lining
ascending (65%)
arch (10%)
descending (20%)

Why?
collagen elastin abnormality
cystic medial necrosis
Intramural hematoma
No intimal tear
medial hemorrhage

Who?
HTN
vasculitis
50-70 yo males >females
Diagnosis
CT scan
sensitivity 96-100%
specificity 96-100%
Ptifalls- motion thru aortic root (can ecg gate)
renal insufficiency
contrast allergy
MRI
sens= 98%
spec= 98%
Pitfalls long study not for unstable patient
no iodine
less motion artifact if ecg gated
can quantitiate aortic insufficiency
Complications
Death: 25% first 24 hrs
50% first week
Aortic insufficiency
pericardial hematoma and tamponade
MI
branch artery occlusion
rupture leak
Famous deaths
King George II
John Ritter

Bone Scintigraphy Identifies Potential Responders to Plantar Fasciitis Treatment

Scan classification showing blood-pool phase at top and delayed phase at bottom: focal hyperemia in plantar fascia and marked delayed uptake in inferior calcaneum (A), hyperemia in proximal third and mild delayed uptake (B), and diffuse hyperemia and moderate delayed uptake (C). Arrowheads indicate hyperemia; arrows indicate delayed uptake. Copyright © 2006 by the Society of Nuclear Medicine.

Scintigraphy pegs potential responders to plantar fasciitis treatment

10/25/2006By: Plantar fasciitis is the most common cause of heel pain but the differential diagnosis can include Achilles tendinitis, retrocalcaneal bursitis, and calcaneum fracture. Bone scintigraphy is often used to identify the source of heel pain, and the modality may play a predictive role in treatment as well, according to a study in the Journal of Nuclear Medicine.

"Injections of corticosteroids or local anesthetics remain a convenient form of therapy," wrote Dr. Clayton Frater and colleagues. "Bone scintigraphy has also been shown to be an accurate guide in selecting injection sites.... We present scintigraphic criteria that can help identify potential responders (to therapy)..." (JNM, October 2006, Vol. 47:10, pp. 1577-1580).
Frater is from the University of Sydney in Australia. Other co-authors are from the University of New South Wales and Concord Hospital, both in Sydney, as well as King's College in London.
For this study, scintigraphy scans from 24 patients diagnosed with plantar fasciitis, and treated with local injection of steroids or anesthetics, were included. In addition, scans from 10 patients with other conditions were thrown into the mix to test the specificity of scintigraphy.

Imaging was done with a high-resolution collimator affixed to a gamma camera (Millennium or 400AC, GE Healthcare, Chalfont St. Giles, U.K.) after a 900- to 1,000-MBq injection of Tc-99m methylene diphosphonate. Blood-pool images of the plantar aspect of both feet were obtained, as were delayed images of the anterior, posterior, lateral/medial, and plantar aspects of the feet.
Patient responses were followed up at four to five weeks. Abnormalities of the blood-pool phase were characterized as focal calcaneal hyperemia, extension into the proximal third of the plantar fascia, diffuse involvement of the plantar fascia, or no evidence of hyperemia within the plantar fascia. Delayed images were classified based on the degree of calcaneal uptake.

In total, 32 injections were performed in 24 patients with complete or near relief from pain reported in 20 feet. Of the 20 that responded to treatment, 14 feet showed focal hyperemia and six showed minimal extension, the authors stated, adding that they found a significant difference between patients with focal hyperemia and diffuse blood-pool abnormalities (p = 0.004).

On the delayed images of the 20 responders, eight feet demonstrated mild inferior calcaneal uptake, six showed moderate uptake, and six had severe uptake.

"The blood-pool studies had good reproducibility, with a k-value of 0.64 (95% confidence interval [CI]). Agreement on reporting the delayed images was also good, with a k-score of 0.66 (95% CI)," the authors wrote. Interobserver agreement was fair with a k-value of 0.55, they reported.

"Focal calcaneal hyperemia is clearly associated with a high success rate for injection, with extension of hyperemia into the proximal soft tissues being associated with a response in only 50% and diffuse hyperemia with no response," the authors concluded. Using imaging criteria, clinicians can rule out patients who would not benefit from injection therapy, they added.

I thought this might be of interest to Podiatry Residents who rotate through.

Source: Shalmali Pal. AuntMinnie.com staff writerOctober 25, 2006

There is a very excellent podcast related to Nuclear Medicine and Molecular Medicine that can be found at http://nucmedpodcast.blogspot.com/ as well as at Itunes. As stated on the home page this podcast is "intended to be a community podcast with you the nuclear medicine professionals and users as the driving force. Please email suggestions, audio comments, and volunteers for podcast interviews. nucmedpodcast@gmail.com" I have been a regular listener since episode 1. (Nov 05: congrats on one year anniversary) What I like best about the podcast is that it gives an international view of whats going on in NUCS which is nice for someone from North America to get exposure to.

Lung CA II PET / CT

Click image for full size
This is just a quick update to show a VR PET /CT of a left hilar lung cancer. This is a PET image fused to an average intensity projection image. I think it demonstrates nicely the relationship of the tumor uptake to the airway and the left upper lobe post obstructive pneumonia

In an earlier post I mentioned Amide as a nice freeware for image fusion. I should give equal time to MIM. This CLEVELAND based company founded by Dennis Nelson PhD makes terrific visualization software for nuclear imaging and medical imaging in general. It is actually what we use most for daily PET/CT reading. The reason is that it is very intuitive and does a great job streamlining PET /CT work flow. They are also doing a great job integrating their software with PACS systems.

VR PET/CT Tongue Base Cancer

Click image for full size

Volume rendered PET/CT. There is a mid line squamous cell Ca of the tongue base. There is no adenopathy. We are seeing an increase in the number of patients with head and neck Ca being referred for PET/CT. As stated in an earlier post PET/CT's impact on staging and initial therapy decisions is significant.